Turkiye Klinikleri Journal of Biostatistics

.: ORIGINAL RESEARCH
Whole Genome microRNA Expression Data in Childhood Acute Lymphoblastic Leukemia and Evaluation of microRNA Pathways Using Fuzzy C-means
Çocukluk Çağı Akut Lenfoblastik Lösemide Tüm Genom mikroRNA İfade Verileri ve Bulanık C-ortalamaları Kullanılarak mikroRNA Yolaklarının Değerlendirilmesi
Su ÖZGÜRa, Mehmet Nurullah ORMANa, Bakiye GÖKER BAĞCAb, Muhterem DUYUc, Özgür ÇOĞULUd
aDepartment of Biostatistics and Medical Informatics, Ege University Faculty of Medicine, İzmir, TURKEY
bDepartment of Medical Biology, Ege University Faculty of Medicine, İzmir, TURKEY
cDepartment of Pediatric Health and Diseases, Medeniyet University Göztepe Training and Research Hospital, İstanbul, TURKEY
dDepartment of Medical Genetics, Ege University Faculty of Medicine, İzmir, TURKEY
Turkiye Klinikleri J Biostat. 2021;13(1):70-81
doi: 10.5336/biostatic.2020-79777
Article Language: EN
Full Text
ABSTRACT
 Objective: Hard clustering approaches may cause some of the relationships to be overlooked due to their nature of algorithms especially in genetic datasets. But hidden relationships can be revealed by fuzzy approaches. Purpose of this study was evaluating effect of microRNAs (miRNA) on children with acute lymphoblastic leukaemia (ALL) by using miRNA expression data obtained from bone marrow samples with sets containing different numbers of elements of fuzzy C-means (FCM). Material and Methods: miRNA expression levels of 43 newly diagnosed ALL patients and 14 healthy subjects were analysed via FCM. Clusters containing different numbers of miRNAs were evaluated, common properties in messenger RNA (mRNA) pathways were investigated and new pathways associated with ALL and cancer were described via miRNA target prediction tools. Results: Significant miRNA profile was compared to control cases. Only 46 out of 108 miRNAs were found to be significantly upregulated or downregulated. Of forty six miRNAs: 8 miRNAs were labelled as tumour suppressor (17.4%), 17 miRNAs were labelled as onco-miR (37.0%) and 21 miRNAs could not be labelled (45.6%) for hematological malignancy. Fourteen (%30.4) miRNAs were found to be apoptosis-related, 27 miRNAs were in leukemia-related (58.7%) and 15 labelled miRNAs were related with cancer pathways (32.6%). hsa-miR-181b, hsa-miR-146a, hsa-miR-155, hsa-miR-181c-5p, hsa-miR-7-1-3p, hsa-miR-708-5p onco-miRs constituted a set. These miRNAs targeted 801 common mRNAs (p<0.05). When this sub-cluster was searched in the literature and miRNA target prediction tools system, it was found to be involved in cancer-related pathways except ALL. Conclusion: Hidden relation-ships can be defined by fuzzy approaches and those pathways may pro-vide guidance to open up new horizons in the field of miRNA studies.

Keywords: Fuzzy C means algorithm; miRNA; childhood cancers; miRNA target prediction tools
ÖZET
 Amaç: Sert kümeleme yaklaşımları, özellikle genetik veri setle-rinde algoritmaların doğası gereği bazı ilişkilerin gözden kaçmasına neden olabilmektedir. Ancak gizli ilişkiler, bulanık yaklaşımlarla ortaya çıkarılabilir. Bu çalışmanın amacı, mikroRNA'ların (miRNA) akut lenfoblastik lösemili (ALL) çocuklar üzerindeki etkisini, bulanık C-ortalaması (FCM) ile elde edilen ve farklı sayıda kümeleri içeren setlerle kemik iliği örneklerinden elde edilen miRNA ekspresyon verilerini kul-lanarak değerlendirmektir. Gereç ve Yöntemler: Kırk üç yeni tanılı ALL hastası ve 14 sağlıklı çocuğun miRNA ekspresyon seviyeleri FCM ile analiz edilmiştir. Farklı sayıda miRNA içeren kümeler değerlendiri-lerek, mesajcı RNA (mRNA) yolaklarındaki ortak özellikler araştırılmış, ALL ve kanserle ilişkili yeni yolaklar miRNA hedef tahmin araçlarıyla tanımlanmıştır. Bulgular: Anlamlı miRNA düzeyleri, kontrol vakalarıy-la karşılaştırılmıştır. Yüz sekiz miRNA'dan sadece 46'sının önemli öl-çüde yüksek regüle veya düşük regüle edildiği bulunmuştur. Kırk altı miRNA'dan, 8 (%17,4) miRNA tümör baskılayıcı, 17 (%37,0) miRNA onco-miR olarak tanımlanırken, 21 (%45,6) miRNA hematolojik malignite için tanımlanamamıştır. Tanımlanan 14 (%30,4) miRNA apoptozla ilişkili, 27 (%58,7) miRNA lösemi ile ilişkili ve 15 (%32,6) miRNA kanser yolakları ile ilişkili saptanmıştır. hsa-miR-181b, hsa-miR-146a, hsa-miR-155, hsa-miR-181c-5p, hsa-miR-7-1-3p, hsa-miR-708-5p onko-miR'leri bir küme oluşturmaktadır. Bu miRNA'lar, 801 ortak mRNA'yı hedeflemiştir (p<0,05). Literatürde ve miRNA hedef tahmin araçları sisteminde, bu alt küme ilişkisi araştırıldığında, ALL dışındaki kansere bağlı yolaklarda rol oynadıkları görülmüştür. Sonuç: Gizli ilişkiler bulanık yaklaşımlarla tanımlanabilir ve bu yolaklar, miRNA çalışmaları alanında yeni ufuklar açmak için rehberlik sağlaya-bilir.

Anahtar Kelimeler: Bulanık C ortalamalar algoritması; miRNA; çocukluk çağı kanserleri; miRNA hedef tahmin araçları
REFERENCES:
  1. Greene CS, Tan J, Ung M, Moore JH, Cheng C. Big data bioinformatics. Journal of Cellular Physiology. 2014;229(12):1896-1900. [Crossref]  [PubMed]  [PMC] 
  2. Vardhan A, Sarmah P, Das A. A Comprehensive Analysis of the Most Common Hard Clustering Algorithms. In: Smys S, Bestak R, Rocha Á, eds. Inventive Computation Technologies. ICICIT 2019. Lecture Notes in Networks and Systems, Springer, Cham. vol 98. 2020. [Crossref] 
  3. Scaria T, Stephen G, Mathew J. Gene expression data analysis using fuzzy C-means clustering technique. International Journal of Computer Applications. 2016;135(8):33-6. [Crossref] 
  4. Li X, Lu X, Tian J, Gao P, Kong H, Xu G, et al. Application of fuzzy c-means clustering in data analysis of metabolomics. Anal Chem. 2009;1;81(11):4468-75. [Crossref]  [PubMed] 
  5. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3-4):369-78. [Crossref]  [PubMed] 
  6. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11(12):1753-61. [Crossref]  [PubMed]  [PMC] 
  7. Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L, Congdon CB, et al. Common features of microRNA target prediction tools. Front Genet. 2014;18;5:23. [Crossref]  [PubMed]  [PMC] 
  8. Hofacker IL, Fontana W, Stadler PF, Bonhoeffer LS, Tacker M, Schuster P. Fast folding and comparison of RNA secondary structures. Monatshefte für Chemie/Chemical Monthly. 1994;125(2):167-88. [Crossref] 
  9. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39(Database issue):D152-7. [Crossref]  [PubMed]  [PMC] 
  10. Laganà A, Forte S, Giudice A, Arena MR, Puglisi PL, Giugno R, et al. miRò: a miRNA knowledge base. Database (Oxford). 2009;2009:bap008. [Crossref]  [PubMed]  [PMC] 
  11. Wang YF, Yu ZG, Anh V. Fuzzy C-means method with empirical mode decomposition for clustering microarray data. Int J Data Min Bioinform. 2013;7(2):103-17. [Crossref]  [PubMed] 
  12. Macneil LT, Walhout AJM. Gene regulatory networks and the role of robustness and stochasticity in the control of gene expression. Genome Research. 2011;21:645-57. [Crossref]  [PubMed]  [PMC] 
  13. Lloyd A. Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Methods of Biochemical Analysis, 43). Briefings in Bioinformatics. 2001;2(4):407-8. [Crossref] 
  14. Bezdek J. Corrections for "FCM: the fuzzy C-means clustering algorithm." Computers & Geosciences. 1985;11(5):660. [Crossref] 
  15. Kim SY, Lee JW, Bae JS. Effect of data normalization on fuzzy clustering of DNA microarray data. BMC Bioinformatics. 2006;7:134. [Crossref]  [PubMed]  [PMC] 
  16. Duyu M, Durmaz B, Gunduz C, Vergin C, Yilmaz Karapinar D, Aksoylar S, et al. Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia. Biomed Res Int. 2014;2014:967585. [Crossref]  [PubMed]  [PMC] 
  17. [Link]  (Erişim tarihi 14.04.2021)
  18. [Link]  (Erişim tarihi 14.04.2021)
  19. KEGG Pathway Database [Internet]. Wiring diagrams of molecular interactions, reactions and relations. Available from: [Link]  (Erişim Tarihi: 14.04.2021)
  20. [Link]  (Erişim tarihi 14.04.2021)
  21. TargetScanHuman [Internet]. Search for predicted microRNA targets in mammals. © 2006-2018 Whitehead Institute for Biomedical Research. Available from: (erişim tarihi: 14.04.2021) [Link] 
  22. Del Vescovo V, Denti MA. microRNA and Lung Cancer. Adv Exp Med Biol. 2015;889:153-77. [Crossref]  [PubMed] 
  23. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;15;65(16):7065-70. [Crossref]  [PubMed] 
  24. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;8;102(10):3627-32. [Crossref]  [PubMed]  [PMC] 
  25. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. PNAS. 2007;104(41):16170-5. https://www.pnas.org/content/104/41/16170 [Crossref]  [PubMed]  [PMC] 
  26. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;6;129(1):147-61. [PubMed] 
  27. Ma Z, Qiu X, Wang D, Li Y, Zhang B, Yuan T, et al. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(8):630-8. [Crossref]  [PubMed] 
  28. Li Y, Kuscu C, Banach A, Zhang Q, Pulkoski-Gross A, Kim D, et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. Cancer Res. 2015;1;75(13):2674-85. [Crossref]  [PubMed]  [PMC] 
  29. He S, Zeng S, Zhou ZW, He ZX, Zhou SF. Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication. Drug Des Devel Ther. 2015;18;9:1103-75. [Crossref]  [PubMed]  [PMC] 
  30. Korhan P, Erdal E, Atabey N. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun. 2014;8;450(4):1304-12. [Crossref]  [PubMed] 
  31. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010;13;115(19):3916-22. [Crossref]  [PubMed]  [PMC] 
  32. Pekarsky Y, Croce CM. Role of miR-15/16 in CLL. Cell Death Differ. 2015;22(1):6-11. [Crossref]  [PubMed]  [PMC] 
  33. Zanesi N, Balatti V, Bottoni A, Croce CM, Pekarsky Y. Novel insights in molecular mechanisms of CLL. Curr Pharm Des. 2012;18(23):3363-72. [Crossref]  [PubMed] 
  34. Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y, et al. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. J Transl Med. 2015;13;289:2-15. [Link] 
  35. Xu H, Hu YW, Zhao JY, Hu XM, Li SF, Wang YC, et al. MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma. Oncol Rep. 2015;34(1):175-82. [Crossref]  [PubMed] 
  36. Luo Q, Wei C, Li X, Li J, Chen L, Huang Y, et al. MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep. 2014;31(3):1096-102. [Crossref]  [PubMed]  [PMC] 
  37. Luo Q, Zhang Z, Dai Z, Basnet S, Li S, Xu B, et al. Tumor-suppressive microRNA-195-5p regulates cell growth and inhibits cell cycle by targeting cyclin dependent kinase 8 in colon cancer. Am J Transl Res. 2016;15;8(5):2088-96. [PubMed]  [PMC] 
  38. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva WA Jr, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 2007;40(11):1435-40. [Crossref]  [PubMed] 
  39. Zhi F, Wang Q, Deng D, Shao N, Wang R, Xue L, et al. MiR-181b-5p downregulates NOVA1 to suppress proliferation, migration and invasion and promote apoptosis in astrocytoma. PLoS One. 2014;9;9(10):e109124. [PubMed]  [PMC] 
  40. Retraction Statement: "Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL" by Xue Li, MMed, Dong Li, PhD, Yong Zhuang, MMed, Qing Shi, BSc, Wei Wei, MMed, and Xiuli Ju, MD, PhD. Pediatr Blood Cancer. 2017;64(5). [Crossref]  [PubMed] 
  41. Uzhga-Rebrov O, Kule?hova G. Problems of fuzzy clustering of microarray data. IT and Management Science. 2010;44(1):51-4. [Crossref] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com